Join
Live feed
·
INSIDERFilingvia Quantisnow
Taysha Gene Therapies Inc. logo

President and Head of R&D Nagendran Sukumar was granted 324,500 shares, increasing direct ownership by 36% to 1,222,343 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
TSHA· Taysha Gene Therapies Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TSHA (Taysha Gene Therapies Inc.) and more on Quantisnow.